BIO Stock Summary and Trading Ideas (Bio-Rad Laboratories Class A | NYSE:BIO)

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Bio-Rad Laboratories Class A trades on the NYSE stock market under the symbol BIO.

As of February 13, 2026, BIO stock price declined to $256.00 with 832,961 million shares trading.

BIO has a beta of 0.76, meaning it tends to be less sensitive to market movements. BIO has a correlation of 0.09 to the broad based SPY ETF.

BIO has a market cap of $6.91 billion. This is considered a Mid Cap stock.

Last quarter Bio-Rad Laboratories Class A reported $693 million in Revenue and $2.51 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.14.

In the last 3 years, BIO traded as high as $509.62 and as low as $211.43.

The top ETF exchange traded funds that BIO belongs to (by Net Assets): VTI, IJH, VB, VBR, VXF.

BIO has underperformed the market in the last year with a price return of -18.0% while the SPY ETF gained +14.5%. BIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.8% and -13.2%, respectively, while the SPY returned +0.3% and -1.5%, respectively.

BIO support price is $285.83 and resistance is $299.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIO shares will trade within this expected range on the day.